![]() |
|
|
Vol. 280, Issue 3, 1304-1311, 1997
Analytical and Metabolic Research Laboratories (H.I., K.K., H.N.,
K.S., Y.K.), Sankyo Co., Ltd., Tokyo, Japan and the
Faculty of
Pharmaceutical Sciences (K.N., H.S., Y.S.), The University of Tokyo,
Tokyo, Japan
Temocapril · HCl
(
-{(2S,6R)-6-[(1S)-1-ethoxy-carbonyl-3-phenyl-propyl]amino-5-oxo-2-(2-thienyl)perhydro-1,4-thiazepin-4yl}acetic acid hydrochloride) is a novel prodrug of an angiotensin-converting enzyme (ACE) inhibitor. Unlike many other ACE inhibitors, its pharmacologically active metabolite,temocaprilat, is excreted predominantly in bile. To investigate the mechanism for the biliary excretion of temocaprilat, we performed in vivo and in
vitro experiments using mutant Eisai hyperbilirubinemic rats EHBR)
whose canalicular multispecific organic anion transporter (cMOAT) is
hereditarily defective. Biliary clearance of temocaprilat after i.v.
administration of [14C]temocapril · HCl (1.0 mg/kg) in
EHBR was significantly lower than that in Sprague-Dawley rats (5.00 ml/min/kg for Sprague-Dawley rats vs. 0.25 ml/min/kg for
EHBR). The uptake of temocaprilat into canalicular membrane vesicles
(CMVs) prepared from Sprague-Dawley rats was stimulated in the presence
of ATP, whereas little stimulation was observed in CMVs from EHBR. The
initial uptake rate of ATP-dependent transport of temocaprilat showed
saturation kinetics; we obtained an apparent
Vmax value of 1.14 nmol/min/mg protein and a
Km value 92.5 µM. ATP-dependent transport of
temocaprilat was competitively inhibited by
2,4-dinitrophenyl-S-glutathione, a typical substrate for
cMOAT with an inhibition constant (Ki) of 25.8 µM. The Km value for the uptake of
2,4-dinitrophenyl-S-glutathione into CMVs (Km = 29.6 µM) was consistent with this
Ki value. In addition, the ATP-dependent uptake
of 2,4-dinitrophenyl-S-glutathione was inhibited by
temocaprilat in a concentration-dependent manner. Active forms of some
ACE inhibitors (benazepril, cilazapril, delapril, enalapril and
imidapril) did not affect the transport of temocaprilat into CMVs even
at concentrations as high as 200 µM. These data suggest that
temocaprilat is effectively excreted in bile via cMOAT that
is deficient in EHBR and that many of other ACE inhibitors have low
affinity for cMOAT.
This article has been cited by other articles:
![]() |
T. Watanabe, K. Maeda, T. Kondo, H. Nakayama, S. Horita, H. Kusuhara, and Y. Sugiyama Prediction of the Hepatic and Renal Clearance of Transporter Substrates in Rats Using in Vitro Uptake Experiments Drug Metab. Dispos., July 1, 2009; 37(7): 1471 - 1479. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hu, K. E. Sampson, B. R. Heyde, K. M. Mandrell, N. Li, A. Zutshi, and Y. Lai Saturation of Multidrug-Resistant Protein 2 (Mrp2/Abcc2)-Mediated Hepatobiliary Secretion: Nonlinear Pharmacokinetics of a Heterocyclic Compound in Rats after Intravenous Bolus Administration Drug Metab. Dispos., April 1, 2009; 37(4): 841 - 846. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Abe, A. S. Bridges, and K. L. R. Brouwer Use of Sandwich-Cultured Human Hepatocytes to Predict Biliary Clearance of Angiotensin II Receptor Blockers and HMG-CoA Reductase Inhibitors Drug Metab. Dispos., March 1, 2009; 37(3): 447 - 452. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Liu, Y. Cui, A. Y. Chung, Y. Shitara, Y. Sugiyama, D. Keppler, and K. S. Pang Vectorial Transport of Enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in Rat and Human Livers J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 395 - 402. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nishiya, H. Kataoka, K. Mori, M. Goto, T. Sugawara, and K. Furuhama Tienilic Acid Enhances Hyperbilirubinemia in Eisai Hyperbilirubinuria Rats through Hepatic Multidrug Resistance-Associated Protein 3 and Heme Oxygenase-1 Induction Toxicol. Sci., June 1, 2006; 91(2): 651 - 659. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Imai, M. Imoto, H. Sakamoto, and M. Hashimoto IDENTIFICATION OF ESTERASES EXPRESSED IN CACO-2 CELLS AND EFFECTS OF THEIR HYDROLYZING ACTIVITY IN PREDICTING HUMAN INTESTINAL ABSORPTION Drug Metab. Dispos., August 1, 2005; 33(8): 1185 - 1190. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ninomiya, K. Ito, and T. Horie FUNCTIONAL ANALYSIS OF DOG MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2 (MRP2) IN COMPARISON WITH RAT MRP2 Drug Metab. Dispos., February 1, 2005; 33(2): 225 - 232. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fukunari, K. Okamoto, T. Nishino, B. T. Eger, E. F. Pai, M. Kamezawa, I. Yamada, and N. Kato Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic Acid]: A Potent Xanthine Oxidoreductase Inhibitor with Hepatic Excretion J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 519 - 528. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sasaki, H. Suzuki, J. Aoki, K. Ito, P. J. Meier, and Y. Sugiyama Prediction of in Vivo Biliary Clearance from the in Vitro Transcellular Transport of Organic Anions across a Double-Transfected Madin-Darby Canine Kidney II Monolayer Expressing Both Rat Organic Anion Transporting Polypeptide 4 and Multidrug Resistance Associated Protein 2 Mol. Pharmacol., September 1, 2004; 66(3): 450 - 459. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama Impact of Drug Transporter Studies on Drug Discovery and Development Pharmacol. Rev., September 1, 2003; 55(3): 425 - 461. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kirima, K. Tsuchiya, H. Sei, T. Hasegawa, M. Shikishima, Y. Motobayashi, K. Morita, M. Yoshizumi, and T. Tamaki Evaluation of systemic blood NO dynamics by EPR spectroscopy: HbNO as an endogenous index of NO Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H589 - H596. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. Fromm, H.-M. Kauffmann, P. Fritz, O. Burk, H. K. Kroemer, R. W. Warzok, M. Eichelbaum, W. Siegmund, and D. Schrenk The Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters Am. J. Pathol., November 1, 2000; 157(5): 1575 - 1580. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. M. H. Van Aubel, R. Masereeuw, and F. G. M. Russel Molecular pharmacology of renal organic anion transporters Am J Physiol Renal Physiol, August 1, 2000; 279(2): F216 - F232. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ishizuka, K. Konno, T. Shiina, H. Naganuma, K. Nishimura, K. Ito, H. Suzuki, and Y. Sugiyama Species Differences in the Transport Activity for Organic Anions across the Bile Canalicular Membrane J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1324 - 1330. [Abstract] [Full Text] |
||||
![]() |
K. Niinuma, Y. Kato, H. Suzuki, C. A. Tyson, V. Weizer, J. E. Dabbs, R. Froehlich, C. E. Green, and Y. Sugiyama Primary active transport of organic anions on bile canalicular membrane in humans Am J Physiol Gastrointest Liver Physiol, May 1, 1999; 276(5): G1153 - G1164. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Homma, H. Suzuki, H. Kusuhara, M. Naito, T. Tsuruo, and Y. Sugiyama High-Affinity Efflux Transport System for Glutathione Conjugates on the Luminal Membrane of a Mouse Brain Capillary Endothelial Cell Line (MBEC4) J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 198 - 203. [Abstract] [Full Text] |
||||
![]() |
H. Ishizuka, K. Konno, H. Naganuma, K. Nishimura, H. Kouzuki, H. Suzuki, B. Stieger, P. J. Meier, and Y. Sugiyama Transport of Temocaprilat into Rat Hepatocytes: Role of Organic Anion Transporting Polypeptide J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 37 - 42. [Abstract] [Full Text] |
||||
![]() |
T. Hirohashi, H. Suzuki, K. Ito, K. Ogawa, K. Kume, T. Shimizu, and Y. Sugiyama Hepatic Expression of Multidrug Resistance-Associated Protein-Like Proteins Maintained in Eisai Hyperbilirubinemic Rats Mol. Pharmacol., June 1, 1998; 53(6): 1068 - 1075. [Abstract] [Full Text] |
||||
![]() |
K. Ito, H. Suzuki, T. Hirohashi, K. Kume, T. Shimizu, and Y. Sugiyama Functional Analysis of a Canalicular Multispecific Organic Anion Transporter Cloned from Rat Liver J. Biol. Chem., January 16, 1998; 273(3): 1684 - 1688. [Abstract] [Full Text] [PDF] |
||||